SITE002-0188

SITE002 (USA) › SITE002-0188

SITE002-0188

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE002 (USA) · Dr. Nolan
consented 2026-04-14

enrolled

AEs

2

Serious

0

Dropout signal

–

Adverse events

2

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-11-26 (study day 31); relationship: not assessed

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-11-24 (study day 29); relationship: NOT RELATED

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.